GLV offers differentiated access to the metabolic health market. Backed by a proprietary supply chain, an AI operations layer, and a founder who has been inside these businesses for two decades.
The metabolic health market is fragmented, undercapitalized, and at an inflection point. It favors a platform acquirer with real clinical and operational depth.
Buy at independent-clinic multiples. Integrate infrastructure no independent can build alone. Exit at platform multiples to PE or strategic buyers already acquiring in adjacent categories.
The supply chain and AI layer are what make this work. Neither can be replicated quickly by a financial buyer starting from scratch.
Independent clinics at $500K–$5M revenue. Fragmented, undervalued, no efficient market for these deals yet.
Golden Lotus Labs goes in within 60–90 days. Cost structure improves immediately. Margin captured on both sides.
Patient acquisition, billing optimization, retention, and workflow systems. Revenue per patient increases. Overhead decreases.
Each acquisition makes the next one more valuable: shared infrastructure, supply chain scale, and cross-clinic data.
Platform sale to PE or strategic buyer. $50M–$100M revenue target. 15–25 clinic locations. 5-year horizon.
The GLV moat isn't a slide. It's an operating business. Golden Lotus Labs is live. The AI platform is deployed. The clinical knowledge comes from being inside these businesses for two decades.
Operating under FDA guidelines today. Margin on both the acquisition and supply side. A structural advantage no financial buyer starts with.
Not a roadmap. An operational system with real clinic data behind it. Deploys in weeks, not quarters.
We know what GLP-1 pipeline depth means for a practice valuation, what peptide mix signals about patient LTV, and where the adjacent revenue is hiding.
Independent clinic owners don't sell to financial buyers who don't understand their business. They sell to operators who have been in the room.
GLV is actively fundraising and building its board. If you're an investor looking for differentiated healthcare exposure with an operator at the helm, let's talk.
Investor Inquiries